Skip to main content

Belite Bio, Inc

BLTE
Exchange
Nasdaq
Industry
Pharmaceutical Preparations
SEC CIK
0001889109

In the last 90 days, Belite Bio, Inc insiders filed 0 open-market purchases and 4 sales; 80 institutions reported holding it in 13F filings for Q2 2026, worth $1.44B in total; superinvestors Maverick Capital and Duquesne Family Office hold it.

Key figures

Market capADS ratio not in SEC data
–
Insider buysOpen market, last 90 days
0
Insider sellsLast 90 days, $32.3M in total
4
13F holdersQ2 2026, +4 vs. previous quarter
80
13F valueReported value at the end of Q2 2026
$1.44B
Superinvestors holdingAt the end of Q2 2026
2

Price chart

From SEC filings, in USD.

Revenue, FY2025
–
No comparable prior period
Net income, FY2025
-$77.6M
No comparable prior period
Free cash flow, FY2025
-$37.1M
No comparable prior period

Short interest

See short data

From FINRA, settlement date Oct 30, 2026.

Short interest
1.38M
Shares sold short
Change
+113.0K
+8.9% vs. previous
Days to cover
9.96
At average daily volume

Superinvestors holding BLTE, Q2 2026

Go to the superinvestors tab

2 superinvestors report holding Belite Bio, Inc on Form 13F. Percentages are the stock's share of each portfolio.

Maverick Capital

Lee Ainslie

0.6%

Belite Bio, Inc's share of the portfolio

Shares
396,311
Value
$61.0M

Duquesne Family Office

Stanley Druckenmiller

0.4%

Belite Bio, Inc's share of the portfolio

Shares
106,100
Value
$16.3M

Latest insider trades

See all insider trades

Open-market purchases and sales by Belite Bio, Inc insiders from Form 4, newest first.

Insider trades
Filed (ET)Trade dateFiling delayInsiderTransactionSharesAvg priceValueHolding changeFlags
Nov 16, 2026 (view filing)7:13 PM ETNov 124 daysScholl Hendrik PeterChief Medical OfficerSSaleAmerican depositary share−2.00K$165.99−$332.0K−13.8%12.5K after4 lots10b5-1
Oct 5, 2026 (view filing)7:27 PM ETOct 14 daysScholl Hendrik PeterChief Medical OfficerSSaleAmerican depositary share−500$165.32−$82.7K−3.3%14.5K after8 lots10b5-1
Sep 9, 2026 (view filing)7:39 PM ETSep 4-85 daysLin Yu-HsinChief Executive OfficerSSaleAmerican depositary share−100.4K$190.00−$19.1M−58.9%70.1K after19 lots10b5-1
Sep 9, 2026 (view filing)7:38 PM ETSep 4-85 daysChuang Hao-YuanChief Financial OfficerSSaleAmerican depositary share−67.4K$189.98−$12.8M−72.1%26.0K after19 lots10b5-1
Aug 14, 2026 (view filing)6:10 AM ETAug 122 daysChuang Hao-YuanChief Financial OfficerSSaleAmerican depositary share−367$180.35−$66.2K−0.4%93.4K after2 lots10b5-1
Aug 14, 2026 (view filing)6:10 AM ETAug 122 daysLin Yu-HsinChief Executive OfficerSSaleAmerican depositary share−365$180.35−$65.8K−0.2%170.6K after2 lots10b5-1
Jun 22, 2026 (view filing)Jun 184 daysScholl Hendrik PeterChief Medical OfficerSSaleAmerican depositary share−10.0K$145.24−$1.45M−40.0%15.0K after5 lots
Jun 17, 2026 (view filing)Jun 161 dayScholl Hendrik PeterChief Medical OfficerSSaleAmerican depositary share−10.0K$140.57−$1.41M−28.6%25.0K after8 lots
May 8, 2026 (view filing)May 71 dayMata Nathan L.Chief Scientific OfficerSSaleAmerican depositary share−666$153.21−$102.0K−100.0%0 after4 lots10b5-1
May 7, 2026 (view filing)May 61 dayMata Nathan L.Chief Scientific OfficerSSaleAmerican depositary share−1.00K$153.84−$153.8K−60.0%666 after6 lots10b5-1

Top 10 13F holders, Q2 2026

See all 80 holders

The largest institutional positions in Belite Bio, Inc at the end of Q2 2026; share changes are against Q1 2026.

Institutions holding BLTE in Q2 2026
InstitutionSharesValue% of portfolioChange in sharesAction
Darwin Global Management, Ltd.3,077,219$456.6M12.14%+19,807+0.6%Added
Paradigm Biocapital Advisors LP1,232,877$189.8M3.55%+118,093+10.6%Added
RTW Investments, LP715,332$110.2M0.94%00.0%Unchanged
Millennium Management LLC494,564$76.2M0.05%−75,524−13.2%Reduced
Maverick Capital LtdSuperinvestorMaverick Capital396,311$61.0M0.55%+396,311New
Eventide Asset Management, LLC390,829$60.2M0.80%+33,179+9.3%Added
Deerfield Management Company, L.P. (Series C)357,199$55.0M0.57%+53,186+17.5%Added
Holocene Advisors, LP251,035$38.7M0.09%−243,460−49.2%Reduced
Logos Global Management LP250,000$38.5M1.66%+250,000New
Morgan Stanley235,071$36.2M0.00%+33,662+16.7%Added

Holders of 5% or more of BLTE

See all 2 holders and filings

Holders whose latest Schedule 13D or 13G filing reports 5% or more of Belite Bio, Inc.

Largest holders of BLTE from 13D and 13G filings
HolderLatest formStakeChangeFirst filedLatest filingFiling
Lin Bioscience International Ltd.13G53.70%17.1M shares–Feb 14, 20233 filingsJan 21, 2025SEC
Darwin Global Management, Ltd.13G/A8.10%3.03M shares+1.10 ppfrom 7.00%Dec 10, 20252 filingsFeb 17, 2026SEC